Health Care / Chemicals & Pharmaceuticals
Congressional stock trading activity sourced from STOCK Act financial disclosures.
Federal contract context is also available for matched USAspending recipients tied to JNJ.
Total Trades
343
Members
83
Purchases
196
Sales
146
Disclosed late
61
Total disclosed volume: $3,496,343 - $11,890,000 · Latest trade: Sep 8, 2026
Matched federal spending records can add context when a heavily traded company is also receiving public money. These recipient matches come from USAspending and should be read alongside, not instead of, the underlying trade filings.
Matched recipients
2
Tracked awards
96
Matched spending
$3M
JOHNSON & JOHNSON matches USAspending recipient DEPUY SYNTHES SALES, INC., with approximately $2,579,303 in tracked federal spending during the queried window.
JOHNSON & JOHNSON matches USAspending recipient JANSSEN BIOTECH INC, with approximately $464,811 in tracked federal spending during the queried window.
49
Members
210
Trades
34
Members
133
Trades
10 Form 4 transactions by 3 insiders in the last 90 days. Buys and sales below count open-market transactions only — Form 4 codes P and S. Grants, option exercises and shares withheld for tax move the share count but are not decisions to trade.
Open-market buys
0
Open-market sales
7
Net shares, all codes
−55,054
Buys per sale
0.00
| Insider | Role | Date | Transaction | Shares | Price | Total Value | Filing |
|---|---|---|---|---|---|---|---|
| Taubert Jennifer L | EVP, WWC. Innovative Medicine | Aug 17, 2026 |
Each card is a member's trade in JNJ and an insider's Form 4 transaction in the same ticker dated within seven days of it. One card per member, direction and trade date; where several insiders filed in that week, the card names the filing closest in date and counts the rest. Two dates close together is all a card records.
Lloyd Doggett bought JNJ 2 days before Wengel Kathryn E, EVP, Chief TO and Risk Officer, reported exercised options on a Form 4.
Lloyd Doggett bought JNJ 2 days before Wengel Kathryn E, EVP, Chief TO and Risk Officer, reported sold on a Form 4.
John Boozman sold JNJ 3 days after Taubert Jennifer L, EVP, WWC. Innovative Medicine, reported exercised options on a Form 4. 1 other insider filed in the same week.
| Date▼ | Member↕ | Type↕ | Amount↕ | Owner | Disclosed↕ |
|---|---|---|---|---|---|
| Sep 8, 2026 | Lloyd Doggett | purchase | $1,001 - $15,000 | self | Oct 5, 2026 |
| Aug 27, 2026 | Thomas H. Kean, Jr. | sale | $1,001 - $15,000 | self | Sep 12, 2026 |
| Aug 20, 2026 | John Boozman | sale | $1,001 - $15,000 | joint | Sep 11, 2026 |
| Jul 30, 2026 | Richard McCormick | sale | $1,001 - $15,000 | self | Aug 14, 2026 |
| Jun 29, 2026 | Thomas H. Kean, Jr. | sale | $1,001 - $15,000 | self | Jul 15, 2026 |
| Jun 9, 2026 | Lloyd Doggett | purchase | $1,001 - $15,000 | self | Jul 6, 2026 |
| Jun 2, 2026 | Thomas H. Kean, Jr. | sale | $1,001 - $15,000 | self | Jul 15, 2026 |
| Mar 30, 2026 | Alan Armstrong | purchase | $1,001 - $15,000 | self | Jul 21, 2026 |
| Mar 27, 2026 | Alan Armstrong | purchase | $15,001 - $50,000 | self | Jul 21, 2026 |
| Mar 26, 2026 | Thomas H. Kean, Jr. | sale | $1,001 - $15,000 | self | Apr 13, 2026 |
| Mar 19, 2026 | Richard McCormick | sale | $1,001 - $15,000 | self | Apr 7, 2026 |
| Mar 19, 2026 | John Boozman | sale | $1,001 - $15,000 | self | Apr 14, 2026 |
| Mar 19, 2026 | Richard McCormick | sale | $1,001 - $15,000 | self | Apr 7, 2026 |
| Mar 10, 2026 | Lloyd Doggett | purchase | $1,001 - $15,000 | self | Apr 6, 2026 |
| Jan 23, 2026 | Thomas H. Kean, Jr. | sale | $15,001 - $50,000 | self | Feb 19, 2026 |
| Dec 18, 2025 | Julie Johnson | sale | $1,001 - $15,000 | joint | Jan 15, 2026 |
| Dec 9, 2025 | Lloyd Doggett | purchase | $1,001 - $15,000 | self | Jan 2, 2026 |
| Nov 20, 2025 | Thomas H. Kean, Jr. | sale | $15,001 - $50,000 | self | Dec 19, 2025 |
| Nov 13, 2025 | Julie Johnson | sale | $1,001 - $15,000 | joint | Dec 11, 2025 |
| Nov 5, 2025 | Richard McCormick | purchase | $1,001 - $15,000 | self | Dec 9, 2025 |
| Oct 31, 2025 | Lisa C. McClain | sale | $1,001 - $15,000 | spouse | Nov 21, 2025 |
| Oct 30, 2025 | Lisa C. McClain | sale | $1,001 - $15,000 | spouse | Nov 21, 2025 |
| Oct 30, 2025 | Lisa C. McClain | purchase | $1,001 - $15,000 | spouse | Nov 21, 2025 |
| Oct 10, 2025 | Jared Moskowitz | sale | $1,001 - $15,000 | child | Nov 22, 2025 |
| Oct 10, 2025 | Jared Moskowitz | sale | $1,001 - $15,000 | child | Nov 22, 2025 |
Other Health Care stocks traded by members of Congress.
| Open-market sale |
| 15,000 |
| $263.36 |
| $4M |
| SEC Filing |
| Taubert Jennifer L | EVP, WWC. Innovative Medicine | Aug 17, 2026 | Option exercise | 15,000 | $115.67 | $1.7M | SEC Filing |
| Duato Joaquin | CEO and Chairman of the Board | Aug 13, 2026 | Open-market sale | 102,315 | $261.00 | $26.7M | SEC Filing |
| Duato Joaquin | CEO and Chairman of the Board | Aug 13, 2026 | Option exercise | 123,291 | $115.67 | $14.3M | SEC Filing |
| Duato Joaquin | CEO and Chairman of the Board | Aug 13, 2026 | Open-market sale | 20,976 | $262.00 | $5.5M | SEC Filing |
| Forminard Elizabeth | EVP, Chief Legal Officer | Aug 6, 2026 | Open-market sale | 9,344 | $257.75 | $2.4M | SEC Filing |
| Forminard Elizabeth | EVP, Chief Legal Officer | Aug 6, 2026 | Open-market sale | 6,574 | $255.93 | $1.7M | SEC Filing |
| Forminard Elizabeth | EVP, Chief Legal Officer | Aug 6, 2026 | Option exercise | 9,344 | $131.94 | $1.2M | SEC Filing |
| Duato Joaquin | CEO and Chairman of the Board | Aug 5, 2026 | Open-market sale | 41,957 | $258.06 | $10.8M | SEC Filing |
| Duato Joaquin | CEO and Chairman of the Board | Aug 5, 2026 | Open-market sale | 6,523 | $258.74 | $1.7M | SEC Filing |
| Broadhurst Vanessa | EVP, Global Corp Affairs | Jul 20, 2026 | Open-market sale | 23,054 | $251.27 | $5.8M | SEC Filing |
| Broadhurst Vanessa | EVP, Global Corp Affairs | Jul 20, 2026 | Option exercise | 11,925 | $131.94 | $1.6M | SEC Filing |
| Broadhurst Vanessa | EVP, Global Corp Affairs | Jul 20, 2026 | Option exercise | 11,129 | $129.51 | $1.4M | SEC Filing |
| Wengel Kathryn E | EVP, Chief TO and Risk Officer | Jun 11, 2026 | Open-market sale | 10,000 | $241.15 | $2.4M | SEC Filing |
| Wengel Kathryn E | EVP, Chief TO and Risk Officer | Jun 11, 2026 | Option exercise | 10,000 | $115.67 | $1.2M | SEC Filing |
John Boozman sold JNJ 3 days after Taubert Jennifer L, EVP, WWC. Innovative Medicine, reported sold on a Form 4. 1 other insider filed in the same week.
Richard McCormick sold JNJ 6 days before Duato Joaquin, CEO and Chairman of the Board, reported sold on a Form 4. 1 other insider filed in the same week.
Richard McCormick sold JNJ 7 days before Forminard Elizabeth, EVP, Chief Legal Officer, reported exercised options on a Form 4.
AbbVie Inc.